Rakovina and Celvion Partner on AI-Driven Cancer Therapy
Rakovina Celvion partnership uses the EMphora AI platform and real-world clinical data to guide ATR inhibitor development; no financial terms disclosed.
Read More
Ensera Launches Alliance Network for Combination Products
Ensera alliance network links SHL Medical, Stevanato, Ypsomed, Argonaut and American Injectables to speed drug-device combination product supply.
Artificial Organs Market to Top $63 Billion by 2035
Artificial organs market size was $28.71 billion in 2025 and is projected to top $63.31 billion by 2035 at an 8.2% CAGR, led by North America.
AI in Neurosurgery Market to Reach $11.3 Billion by 2035
AI in neurosurgery market size was $850 million in 2025 and is forecast to hit $11.3 billion by 2035 at a 29.5% CAGR, led by North America and software.
Artificial Intelligence in Healthcare Market to Reach $1.14 Trillion by 2035 at 39.1% CAGR
The artificial intelligence in healthcare market was valued at $41.84 billion in 2025 and is projected to reach $1.14 trillion by 2035, a 39.1% CAGR.
Terumo Neuro Arsenal Medical Deal Adds Liquid Embolic
Terumo Neuro Arsenal Medical deal: Terumo Neuro agreed to buy Arsenal Medical and its NeoCast liquid embolic for chronic subdural hematoma.
Tulisokibart Hidradenitis Suppurativa Trial Meets Endpoint
Tulisokibart hidradenitis suppurativa results: Merck’s Phase 2b trial met its HiSCR50 primary endpoint at week 16, with 72% response on the high dose.
FDA Accepts Roche’s Fenebrutinib NDA with Priority Review for Relapsing and Primary Progressive MS
Fenebrutinib priority review: the FDA accepted Roche’s NDA for the BTK inhibitor in relapsing and primary progressive MS, announced 30 September 2026.
Prescription Subscription Plans Gain Momentum as US Insurance Coverage Slips
Amazon’s RxPass and GoodRx’s Companion are gaining momentum as Americans facing rising out-of-pocket costs and shrinking coverage turn to flat-fee prescription subscriptions, a Reuters analysis shows.